Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine WorldBhatia, Anita RaniSaxena, ArpitaTyagi, NitiiiBagra, PeyirBhatia, PaarthPharmaceutical & Biomedical Research
3. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383, 2439–2450 (2020). 4. Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19...
与所有疫苗一样,这些mRNA疫苗的好处是,他们给疫苗接种的人免受病毒感染,而不必感染COVID-19。 Most mRNA vaccines for COVID-19 require you to get a second shot within a few weeks. 2019冠状病毒疾病疫苗需要在数周内注射第二次疫苗...
但新型冠状病毒 (COVID-19) 的疫苗 在不到 11 个月内 in less than 11 months. 通过了紧急使用的临界点。 The secret behind this speed is a medical technology 这速度背后的秘密 that’s been developing for decades: 是数十年医学技术发展的飞跃: the mRNA vaccine. mRNA 疫苗。 This new treatment u...
[3] The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race, Retrieved Nov 10, 2010, from https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/ ...
[1] Nicole Doria-Rose, et al., (2021). Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. The N Engl J Med, DOI: 10.1056/NEJMc2103916 [2] Moderna COVID vaccine offers protection for at least 6 months, study finds. Retrieved April 7, 2021...
虽然目前mRNA效力发挥最出色的领域是COVID-19，但是在多种疾病中mRNA都有很大的治疗潜力，流感、疟疾、乙肝、囊性纤维化、肿瘤等都可能会是mRNA疫苗的下一个突破领域。事实上，癌症其实是mRNA药物最早应用的领域，第一个mRNA疫苗临床试验就是在癌症患者中进行的，mRNA疫苗在新冠感染领域的蓬勃发展也必将带动其它疾病...
在过去几十年里,从被质疑到成功用于临床,尤其是新冠疫情大爆发推动了史上最快速的疫苗开发,mRNA疫苗已在疫苗研发历史上留下了浓墨重彩的一笔。而更令人期待的是,COVID-19并不是mRNA疫苗的唯一“用武之地”,在肿瘤治疗中mRNA疫苗也开始显露头角。 31家mRNA技术公司管线分布(来源:Nat Rev Drug Discov. 2021;10.1...
If an mRNA vaccine works, the implications could stretch far beyond COVID-19. Success could pave the way for the platform’s widespread use for both emerging and established pathogens. “We are really making great strides in vaccine development, which will hopefully change the way vaccines are ...
近期,深圳大学医学部生物医学工程学院助理教授杨成彬/徐周睿与深圳市人民医院临床药师古嘉瑜在Advanced Healthcare Materials杂志上合作发表了题为“Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccine”的综述。